By: ifood.tv

Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events

Aug 16, 2013 No Comments by

Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease
with a high risk of recurrent stroke. A recent trial indicated that clopidogrel and aspirin
treatment reduced the risk of recurrent stroke and was not associated with increased
hemorrhage events, compared with aspirin monotherapy. Apixaban, a new oral anticoagulant, is
proved to be as effective as traditional anticoagulants with less risk of bleeding events.

To estimate whether apixaban is beneficial for acute TIA or minor stroke, a randomized,
double-blind, multicenter, controlled clinical trial has been designed. The investigators
will assess the hypothesis that a 21-days apixaban regimen is superior to clopidogrel and
aspirin dual-therapy for the treatment of high-risk patients with acute nondisabling
cerebrovascular event.

Clinical Trial Conditions: Ischemic Stroke, TIA

Treatments in this Clinical Trial : Apixaban, Clopidogrel, Aspirin, placebo

Eligible Clinical Trial Participant Age : Between 18 years to 80 years

Can Healthy Volunteers Participate: No

Clinical Trial Lead Sponsor: Xijing Hospital

Detailed Clinical Trial Description: Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease
with a high risk of recurrent stroke. A recent trial indicated that clopidogrel and aspirin
treatment reduced the risk of recurrent stroke and was not associated with increased
hemorrhage events, compared with aspirin monotherapy. Apixaban, a new oral anticoagulant, is
proved to be as effective as traditional anticoagulants with less risk of bleeding events.

To estimate whether apixaban is beneficial for acute TIA or minor stroke, a randomized,
double-blind, multicenter, controlled clinical trial has been designed. The investigators
will assess the hypothesis that a 21-days apixaban regimen is superior to clopidogrel and
aspirin dual-therapy for the treatment of high-risk patients with acute nondisabling
cerebrovascular event.

The clinical trial information was obtained from http://clinicaltrials.gov/ct2/show/NCT01924325

New Clinical Trial

About the author

The author didnt add any Information to his profile yet
No Responses to “Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events”

Leave a Reply

By: ifood.tv